2024

Gulliver, C., Busiau, T., Byrne, A., Findlay, J. E., Hoffmann, R. and Baillie, G. (2024) cAMP-phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression. Molecular Oncology, 18(3), pp. 707-725. (doi: 10.1002/1878-0261.13572) (PMID:38126155) (PMCID:PMC10920091)

2023

Gulliver, C., Baillie, G. S. and Hoffmann, R. (2023) Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region. Future Science OA, 9(9), (doi: 10.2144/fsoa-2023-0064) (PMID:37752916) (PMCID:PMC10518809)

Parsons, E. C. , Baillie, G. S. and Hoffmann, R. (2023) Revisiting the roles of cAMP signalling in the progression of prostate cancer. Biochemical Journal, 480(20), pp. 1599-1614. (doi: 10.1042/BCJ20230297)

Gulliver, C., Huss, S., Semjonow, A., Baillie, G. S. and Hoffmann, R. (2023) Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation, and alterations in DNA repair: implications for therapeutic strategies. British Journal of Cancer, (doi: 10.1038/s41416-023-02417-5) (PMID:37740039) (Early Online Publication)

Gulliver, C., Huss, S., Semjonow, A., Baillie, G. S. and Hoffmann, R. (2023) The CAPRA&PDE4D5/7/9 prognostic model is significantly associated to adverse post-surgical pathology outcomes. Cancers, 15(1), 262. (doi: 10.3390/cancers15010262) (PMID:36612262) (PMCID:PMC9818961)

2022

Gulliver, C., Hoffmann, R. and Baillie, G. S. (2022) Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer. International Journal of Biochemistry and Cell Biology, 147, 106230. (doi: 10.1016/j.biocel.2022.106230) (PMID:35609768)

2021

Baillie, G. S. , Gulliver, C. and Hoffmann, R. (2021) The enigmatic helicase DHX9 and its association with the hallmarks of cancer. Future Science OA, 7(2), FSO650. (doi: 10.2144/fsoa-2020-0140) (PMID:33437516) (PMCID:PMC7787180)

2018

van Strijp, D. et al. (2018) The prognostic PDE4D7 score in a diagnostic biopsy prostate cancer patient cohort with longitudinal biological outcomes. Prostate Cancer, 2018, 5821616. (doi: 10.1155/2018/5821616) (PMID:30147955) (PMCID:PMC6083737)

2015

Byrne, A. M., Elliott, C. , Hoffmann, R. and Baillie, G. S. (2015) The activity of cAMP-Phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus. FEBS Letters, 589(6), pp. 750-755. (doi: 10.1016/j.febslet.2015.02.004) (PMID:25680530) (PMCID:PMC4346272)

2014

Henderson, D.J.P., Byrne, A., Dulla, K., Jenster, G., Hoffmann, R., Baillie, G.S. and Houslay, M.D. (2014) The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells. British Journal of Cancer, 110(5), pp. 1278-1287. (doi: 10.1038/bjc.2014.22)

Articles

Gulliver, C., Busiau, T., Byrne, A., Findlay, J. E., Hoffmann, R. and Baillie, G. (2024) cAMP-phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression. Molecular Oncology, 18(3), pp. 707-725. (doi: 10.1002/1878-0261.13572) (PMID:38126155) (PMCID:PMC10920091)

Gulliver, C., Baillie, G. S. and Hoffmann, R. (2023) Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region. Future Science OA, 9(9), (doi: 10.2144/fsoa-2023-0064) (PMID:37752916) (PMCID:PMC10518809)

Parsons, E. C. , Baillie, G. S. and Hoffmann, R. (2023) Revisiting the roles of cAMP signalling in the progression of prostate cancer. Biochemical Journal, 480(20), pp. 1599-1614. (doi: 10.1042/BCJ20230297)

Gulliver, C., Huss, S., Semjonow, A., Baillie, G. S. and Hoffmann, R. (2023) Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation, and alterations in DNA repair: implications for therapeutic strategies. British Journal of Cancer, (doi: 10.1038/s41416-023-02417-5) (PMID:37740039) (Early Online Publication)

Gulliver, C., Huss, S., Semjonow, A., Baillie, G. S. and Hoffmann, R. (2023) The CAPRA&PDE4D5/7/9 prognostic model is significantly associated to adverse post-surgical pathology outcomes. Cancers, 15(1), 262. (doi: 10.3390/cancers15010262) (PMID:36612262) (PMCID:PMC9818961)

Gulliver, C., Hoffmann, R. and Baillie, G. S. (2022) Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer. International Journal of Biochemistry and Cell Biology, 147, 106230. (doi: 10.1016/j.biocel.2022.106230) (PMID:35609768)

Baillie, G. S. , Gulliver, C. and Hoffmann, R. (2021) The enigmatic helicase DHX9 and its association with the hallmarks of cancer. Future Science OA, 7(2), FSO650. (doi: 10.2144/fsoa-2020-0140) (PMID:33437516) (PMCID:PMC7787180)

van Strijp, D. et al. (2018) The prognostic PDE4D7 score in a diagnostic biopsy prostate cancer patient cohort with longitudinal biological outcomes. Prostate Cancer, 2018, 5821616. (doi: 10.1155/2018/5821616) (PMID:30147955) (PMCID:PMC6083737)

Byrne, A. M., Elliott, C. , Hoffmann, R. and Baillie, G. S. (2015) The activity of cAMP-Phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus. FEBS Letters, 589(6), pp. 750-755. (doi: 10.1016/j.febslet.2015.02.004) (PMID:25680530) (PMCID:PMC4346272)

Henderson, D.J.P., Byrne, A., Dulla, K., Jenster, G., Hoffmann, R., Baillie, G.S. and Houslay, M.D. (2014) The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells. British Journal of Cancer, 110(5), pp. 1278-1287. (doi: 10.1038/bjc.2014.22)